BPC-157 Arginate (Stable Form)

Pending PCAC

Also known as: BPC-157 Arginine Salt, BPC-157-Arg

Healing & Recovery

Last reviewed: April 28, 2026

The arginine salt form of BPC-157, developed to improve stability and shelf life compared to the standard acetate salt. BPC-157 arginate maintains the same gastric pentadecapeptide sequence but uses arginine as the counter-ion, which provides better stability at room temperature and in solution. This form is increasingly preferred by compounding pharmacies and researchers.

Mechanism of Action

Same mechanism as standard BPC-157 — upregulates growth factor expression (VEGF, FGF, EGF), promotes angiogenesis, modulates nitric oxide pathways, and interacts with the dopaminergic system. The arginine counter-ion does not change the peptide's pharmacological activity but improves chemical stability, particularly in aqueous solution.

Common Uses

  • Gut healing and GI repair
  • Tendon and ligament recovery
  • Muscle injury repair
  • Neuroprotection
  • Stable alternative to BPC-157 acetate

Known Risks

  • Same risk profile as standard BPC-157
  • No FDA-approved human trials
  • Theoretical concerns about growth factor upregulation
  • Quality varies between sources

Regulatory Status

Pending PCAC

Same regulatory status as BPC-157. Removed from Category 2 on April 15, 2026. Scheduled for PCAC review on July 23, 2026 (Day 1). The arginate form is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.

PCAC Review Scheduled:July 23, 2026View full timeline →

Get notified when the PCAC decides on BPC-157 Arginate (Stable Form)

Scheduled review: July 23, 2026. We'll email you the same day results are announced.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Subcutaneous injection

Typical Dose

250–500 mcg

Frequency

Once or twice daily

Cycle Length

4–8 weeks

Dosing is identical to standard BPC-157 acetate. The arginate form is preferred for stability — longer shelf life reconstituted and better tolerance of temperature variation. Store reconstituted solution refrigerated. Often stacked with TB-500 for synergistic healing.

Related Compounds

Research References

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.